DDInter1553 DDInter1676
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Quetiapine {u} (Compound) resembles {v} (Compound) Trazodone
Quetiapine {u} (Compound) binds {v} (Gene) DRD5
Quetiapine {u} (Compound) upregulates {v} (Gene) SLC11A2
Quetiapine {u} (Compound) palliates {v} (Disease) autistic disorder
Quetiapine {u} (Compound) downregulates {v} (Gene) TM9SF2
Quetiapine {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Quetiapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Quetiapine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Quetiapine (Compound) resembles Trazodone (Compound)
Quetiapine (Compound) binds DRD5 (Gene)
Quetiapine (Compound) upregulates SLC11A2 (Gene)
Quetiapine (Compound) palliates autistic disorder (Disease)
Quetiapine (Compound) downregulates TM9SF2 (Gene)
Quetiapine (Compound) causes Salivary hypersecretion (Side Effect)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Quetiapine may lead to a major life threatening interaction when taken with Clarithromycin